Saturday 17 October 2026
Export SLGL’s income statement to Excel — free account
Sol-Gel Technologies Ltd.
SLGL Healthcare Biotechnology
Sol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS fell 127.1% and free cash flow fell 8.76%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
64.25
4.45
−6.48%
Follow SLGL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (40.85%) | (2.92%) | (23.72%) | (29.59%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
2 | — | 4 | — | |
| (35.11%) | (2.44%) | (18.63%) | (23.17%) | ||
ROIC |
(6,630.24%) | 0.00% | 0.00% | (122.92%) | |
Return on Tangible Assets |
(35.30%) | (2.11%) | (29.26%) | (35.03%) | |
Average Days of Receivables |
144.98 | 21.09 | 37.05 | 189.45 | |
Free Cash Flow per Share |
(6.50) | 0.00 | (7.40) | 0.00 | |
Free Cash Flow |
(21.27) | — | (20.61) | — | |
Capital Expenditures |
(0.04) | — | (0.01) | — | |
| Other line items | |||||
Cash ROIC |
(22.15%) | 0.00% | (44.02%) | 0.00% | |
Accounts Receivable Turnover |
0.33 | 7.46 | 6.97 | 2.25 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
881.34% | 90.70% | 117.62% | 128.71% | |
Selling, General and Administrative Expense of Revenue |
208.64% | 22.18% | 21.54% | 25.19% | |
Share Based Compensation of Revenue |
80.45% | 0.00% | 8.89% | 0.00% | |
Operating CF/Net income |
1.30 | 0.00 | 3.36 | 0.00 | |
Depreciation/Fixed assets |
3.45 | 0.00 | 3.82 | 0.00 | |
Capex/Depreciation |
(0.09) | — | (0.02) | — | |
Revenue per Share |
0.55 | 6.51 | 6.96 | 6.81 | |
Operating CF per Share |
(6.49) | 0.00 | (7.39) | 0.00 | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 |
Columns are period end dates